Inpeco and Grifols partnering to deliver the transfusion medicine ‘lab of the future’
- Inpeco is committed to eliminating human error in diagnostic processes through automation, full sample traceability, and advanced data analytics.
- The alliance with Grifols brings Inpeco’s end-to-end automation solutions to transfusion medicine, ensuring standardized workflows and maximum patient safety.
- Inpeco’s FlexLab™ technology seamlessly integrates with Grifols’ diagnostic systems, providing laboratories with an advanced, scalable, and future-ready solution.
Novazzano, Switzerland, March 20, 2025 – Inpeco advances laboratory outcomes by driving the complete automation of diagnostic workflows to eliminate human error. With the vision of achieving 100% automation, Inpeco ensures that every step of the lab process— from sample collection to final storage— is seamlessly managed by robotic systems, guaranteeing accuracy, efficiency, and traceability. This is especially critical in transfusion medicine, where even the smallest mistake can have life-threatening consequences.
By partnering with Grifols, a global leader in plasma-derived medicines and diagnostic solutions, Inpeco is bringing its open automation system FlexLab™ X to transfusion medicine laboratories.
This ensures that blood and plasma samples are handled with maximum precision, significantly reducing manual intervention and mitigating the risk of errors. Inpeco’s cutting-edge technology automatically dispatches tubes to Grifols analyzers, amongst others, and then, after testing, routes them to refrigerated storage, ensuring full sample traceability. Digital dashboards provide real-time insights into laboratory performance, while the modular and scalable architecture allows labs to adapt to evolving technological advancements.
Inpeco’s dedication to end-to-end automation supports standardized, repeatable, and fully monitored workflows which are especially critical in transfusion medicine where the highest standards of quality and safety must be met. By integrating Inpeco’s automation expertise with Grifols’ industry-leading diagnostic solutions, which include instrumentation, reagents and technical service that screens blood and plasma for possible pathogens as well as performs blood typing for safer transfusions, this collaboration sets a new benchmark for operational excellence and patient safety.
“At Inpeco, we believe that end-to-end automation is key to eliminating errors in diagnostic processes,” said Riccardo Triunfo, CEO of Inpeco. “Especially in transfusion medicine, where precision is non-negotiable, our mission is to ensure that labs operate with the highest levels of safety, efficiency, and accuracy. Our partnership with Grifols reinforces this vision, enabling laboratories to modernize their operations with confidence.”
“Grifols is providing the laboratory of the future,” said Antonio Martínez, president of Grifols Diagnostic Business Unit. “We are extremely pleased to join forces with Inpeco, two global lab technology leaders with a complete solution for labs of any size to fully equip their operations knowing they will have the most advanced and scalable technologies today and in the future.”
This collaboration further strengthens Inpeco’s leadership in Laboratory Automation, advancing its commitment to transforming diagnostic processes through innovation. By combining automation, traceability, and data analytics, Inpeco continues to pave the way for a future where every diagnostic decision is based on fully reliable and error-free data.
Download the media release: “Inpeco and Grifols partnering to deliver the transfusion medicine ‘lab of the future’”
About Inpeco
Inpeco is the global leader in Total Laboratory Automation. The company’s game-changing solutions combine open connectivity with full sample traceability to support secure test results and increase efficiency in clinical laboratories around the world. To date, more than 2700 Inpeco systems have been shipped to 78 countries. Inpeco also provides automation for anatomical pathology labs and is developing solutions for blood banks and life sciences applications. The Group is headquartered in Novazzano, Switzerland, and operates a development and manufacturing facility in Italy, as well as sales and service offices in Europe, the United States and China. For more information, please visit www.inpeco.com
About Grifols
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.
Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.
A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with close to 400 across North America, Europe, Africa and the Middle East, and China.
As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.
Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. For more information, please visit www.grifols.com